Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | CCR4 | P51679 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glymidine SCHEMBL34389 | 0.99 | TDP1 (0.56) | TDP1LMNAMAPK1ALDH1A1KMT2A | |
| Glymidine SCHEMBL27852481 | 0.97 | TDP1 (0.55) | TDP1LMNAMAPK1ALDH1A1KMT2A | |
| SCHEMBL23567060 | 0.84 | LMNA (0.73) | TDP1LMNAALDH1A1KMT2ANPSR1 | |
| SCHEMBL11130757 | 0.80 | LMNA (0.52) | TDP1LMNAALDH1A1KMT2AKDM4E | |
| SCHEMBL21753108 | 0.76 | TSHR (0.60) | TDP1LMNAALDH1A1KDM4ENPSR1 | |
| Acetohexamide SCHEMBL13723464 | 0.75 | LMNA (0.60) | TDP1LMNAALDH1A1KMT2ALIMK2 | |
| SCHEMBL18434115 | 0.75 | KCNH3 (0.53) | LMNAMAPK1KMT2ATSHRMEN1 | |
| Glymidine Sodium SCHEMBL29371260 | 0.74 | L3MBTL1 (0.39) | TDP1MAPK1ALDH1A1KMT2AHTT | |
| SCHEMBL23555262 | 0.74 | LIMK2 (0.64) | LMNAALDH1A1KMT2AHTTLIMK2 | |
| SCHEMBL26806983 | 0.73 | MAPT (0.50) | TDP1LMNAMAPK1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 904 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001450-B1 | DIRECTLY COMPRESSIBLE COMPOSITE FOR ORALLY DISINTEGRATING TABLETS | RUBICON RES PRIVATE LIMITED (IN) | 2019-01-30 | — | — | EP | claimed |
| US-20150051289-A1 | LIQUID FORMULATIONS OF HYPOGLYCAEMIC SULFONAMIDES | AMMTEK (FR) | 2015-02-19 | — | — | US | claimed |
| US-20150050371-A1 | Extract Formulations of Rhodamnia Cinerea And Uses Thereof | BIOTROPICS MALAYSIA BERHAD (MY) | 2015-02-19 | — | — | US | claimed |
| CN-101460150-B | Directly compressible compound for orally disintegrating tablets | RUBICON RES PRIVATE LTD | 2014-02-12 | — | — | CN | claimed |
| WO-2013133685-A1 | EXTRACT FORMULATIONS OF RHODAMNIA CINEREA AND USES THEREOF | BIOTROPICS MALAYSIA BERHAD (MY) | 2013-09-12 | — | — | WO | claimed |
| CN-102885798-A | Orally disintegrating tablet | CHENGDU KANGHONG PHARMACEUTICAL GROUP CO LTD | 2013-01-23 | — | — | CN | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20090208576-A1 | Orally Disintegrating Tablets | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2009-08-20 | — | — | US | claimed |
| CN-101460150-A | Directly compressible compound for orally disintegrating tablets | RUBICON RES PRIVATE LTD (IN) | 2009-06-17 | — | — | CN | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-0580860-B2 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 2004-12-15 | — | — | EP | claimed |
| EP-1334114-A2 | TRANSCOBALAMIN BINDING CONJUGATES USEFUL FOR TREATING ABNORMAL CELLULAR PROLIFERATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2003-08-13 | — | — | EP | claimed |
| US-20020151525-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | COLLINS DOUGLAS A (US) | 2002-10-17 | — | — | US | claimed |
| WO-2002055530-A2 | TRANSCOBALAMIN BINDING CONJUGATES USEFUL FOR TREATING ABNORMAL CELLULAR PROLIFERATION | MAYO FOUNDATION (US) | 2002-07-18 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151525-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | PCNA, MKI67, SLC19A1 | TDP1 1651/4885LMNA 262/4885MAPK1 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.